

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

HOPEWELL PHARMA VENTURES, INC.,
Petitioner,

v.

MERCK SERONO S.A.,
Patent Owner.

Case IPR2023-00480
U.S. Patent No. 7,713,947

**PETITION FOR *INTER PARTES* REVIEW
OF U.S. PATENT NO. 7,713,947**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I. STATEMENT OF PRECISE RELIEF REQUESTED AND REASONS THEREFOR (37 C.F.R. § 42.22(A))..... 1

II. INTRODUCTION 1

III. THE '947 PATENT AND ITS PROSECUTION HISTORY 7

 A. Specification of the '947 patent8

 B. Challenged claims8

 C. The '947 patent prosecution history.....9

IV. STATE OF THE ART BEFORE DECEMBER 22, 2004..... 13

 A. MS is a chronic disease with no known cure13

 B. Immunosuppression was a common treatment strategy; lymphocyte count was a common measure for assessing response to treatment....15

 C. Treatment of MS required cyclical drug therapies.....17

 D. Cladribine, a known immunosuppressant, was used to treat MS before December 2004.....19

 E. Oral cladribine compositions and dosages for treating MS were known in the art.....21

 F. Petitioner's ground relies specifically on the following publications.22

 1. Bodor (EX1022)..... 22

 2. Stelmasiak (EX1013) 24

V. PERSON OF ORDINARY SKILL IN ART 28

VI. CLAIM CONSTRUCTION 29

 A. "total dose of cladribine".....29

 B. "an induction period"29

 C. "a maintenance period"30

VII. IDENTIFICATION OF THE CHALLENGE (37 C.F.R. § 42.104(B)) 33

VIII. GROUND 1: THE CLAIMS WOULD HAVE BEEN OBVIOUS OVER BODOR AND STELMASIAK 33

 A. Claim 3633

1.	A POSA would have had a reason to combine Bodor and Stelmasiak to arrive at the claimed methods	33
2.	A POSA would have had a reasonable expectation of success	43
3.	Each limitation of claim 36 is disclosed in the art.....	45
B.	Claim 38	55
C.	Claim 39	55
D.	Claim 41	56
E.	Claim 42	57
F.	Claim 43	58
G.	Claims 44 and 45.....	59
H.	Claim 46	60
IX.	NO OBJECTIVE INDICIA WEIGH AGAINST THE STRONG OBVIOUSNESS SHOWING HERE	60
X.	THE FACTS AND LAW WEIGH AGAINST DISCRETIONARY DENIAL UNDER § 325(D).....	61
XI.	<i>FINTIV</i> DOES NOT SUPPORT DISCRETIONARY DENIAL.....	65
XII.	<i>GENERAL PLASTIC</i> DOES NOT SUPPORT DISCRETIONARY DENIAL.....	67
XIII.	CERTIFICATION AND STANDING (37 C.F.R. § 42.104(A)).....	68
XIV.	MANDATORY NOTICES (37 C.F.R. § 42.8(A)(1)).....	68

EXHIBIT LIST

<i>Exhibit #</i>	<i>Description</i>
1001	De Luca, G., et al., "Cladribine Regimen for Treating Multiple Sclerosis," U.S. Patent No. 7,713,947 B2 (filed June 18, 2007; issued May 11, 2010)
1002	Declaration of Aaron Miller, M.D.
1003	<i>Curriculum Vitae</i> for Aaron Miller, M.D.
1004	File History for U.S. Patent No. 7,713,947
1005	<i>Intentionally Left Blank</i>
1006	Noseworthy, J.H., et al., "Multiple Sclerosis," <i>The New England Journal of Medicine</i> , 343(13):938-952 (2000)
1007	Neuhaus, O., et al., "Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection," <i>TRENDS in Pharmaceutical Sciences</i> , 24(3):131-138 (2003)
1008	Weiner, H.L., et al., "Immunotherapy of Multiple Sclerosis," <i>Annals of Neurology</i> , 23(3):211-222 (1988)
1009	Wingerchuk, D.M., et al., "Biology of Disease, Multiple Sclerosis: Current Pathophysiological Concepts," <i>Laboratory Investigation</i> , 81(3):263-281 (2001)
1010	Kurtzke, J.F., "Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)," <i>Neurology</i> , 33:1444-1452 (1983)
1011	<i>Intentionally Left Blank</i>
1012	Whitaker, J.N., "Rationale for Immunotherapy in Multiple Sclerosis," <i>Annals of Neurology</i> , 36:S103-S107 (1994)
1013	Stelmasiak, Z., et al., "A pilot trial of cladribine (2-chlorodeoxyadenosine) in remitting-relapsing multiple sclerosis," <i>Medical Science Monitor</i> , 4(1):4-8 (1998)
1014	Beutler, E., et al., "The treatment of chronic progressive multiple sclerosis with cladribine," <i>Proceedings of the National Academy of Sciences, USA</i> 93:1716-1720 (1996)
1015	Tortorella, C., et al., "Cladribine Ortho Biotech Inc.," <i>Current Opinion in Investigational Drugs</i> , 2(12):1751-1756 (2001)
1016	Langtry, H.D., et al., "Cladribine, A Review of its Use in Multiple Sclerosis," <i>BioDrugs</i> , 9(5):419-433 (1998)

<i>Exhibit #</i>	<i>Description</i>
1017	Rudick, R.A., et al., "Management of Multiple Sclerosis," <i>The New England Journal of Medicine</i> , 337(22):1604-1611 (1997)
1018	Rice, G.P.A., et al., "Cladribine and progressive MS, Clinical and MRI outcomes of a multicenter controlled trial," <i>Neurology</i> , 54:1145-1155 (2000)
1019	Barkhof, R., et al., "Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis," <i>Neuroradiology</i> , 36:382-387 (1994)
1020	Pirko, I. and Rodriguez, M., "Pulsed Intravenous Methylprednisolone Therapy in Progressive Multiple Sclerosis: Need for a Controlled Trial," <i>Archives of Neurology</i> , 61:1148-1149 (2004)
1021	Weiner, H.L., et al., "Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group," <i>Neurology</i> , 43:910-918 (1993)
1022	Bodor, N. and Dandiker, Y., "Oral Formulations of Cladribine," International Publication No. WO 2004/087101 A2 (filed March 26, 2004; published October 14, 2004)
1023	Grieb, P., et al., "Effect of Repeated Treatments with Cladribine (2-Chlorodeoxyadenosine) on Blood Counts in Multiple Sclerosis Patients," <i>Archivum Immunologiae Experimentalis</i> , 43:323-327 (1995)
1024	Schultz, T.W., et al., "Cyclodextrine Cladribine Formulations," U.S. Patent No. 6,194,395 B1 (filed February 25, 1999; issued February 27, 2001)
1025	File History for U.S. Patent No. 8,377,903
1026	Beutler, E., "Use of Substituted Adenine Derivatives for Treating Multiple Sclerosis," U.S. Patent No. 5,506,214 B2 (filed February 18, 1993; issued April 9, 1996)
1027	Docket Report, <i>Merck KGaA et al. v. Hopewell Pharma Ventures, Inc.</i> , Case No. 1:22-cv-01365-GBW (D.Del.)
1028	Docket Report, <i>Merck KGaA et al. v. Accord Healthcare, Inc.</i> , Case No. 1:22-cv-00974-GBW (D.Del.)
1029	United States District Courts - National Judicial Caseload Profile, June 2022
1030	<i>Curriculum Vitae</i> for Nancy E. Adams, Ed.D.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.